uric acid has been researched along with Agnogenic Myeloid Metaplasia in 19 studies
Uric Acid: An oxidation product, via XANTHINE OXIDASE, of oxypurines such as XANTHINE and HYPOXANTHINE. It is the final oxidation product of purine catabolism in humans and primates, whereas in most other mammals URATE OXIDASE further oxidizes it to ALLANTOIN.
uric acid : An oxopurine that is the final oxidation product of purine metabolism.
6-hydroxy-1H-purine-2,8(7H,9H)-dione : A tautomer of uric acid having oxo groups at C-2 and C-8 and a hydroxy group at C-6.
7,9-dihydro-1H-purine-2,6,8(3H)-trione : An oxopurine in which the purine ring is substituted by oxo groups at positions 2, 6, and 8.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Primary (PMF) and secondary myelofibrosis (SMF) are myeloproliferative neoplasms characterized by high cellular turnover and substantial risk of thrombosis and death." | 5.72 | Higher serum uric acid is associated with higher risks of thrombosis and death in patients with primary myelofibrosis. ( Galusic, D; Holik, H; Krecak, I; Kusec, R; Lucijanic, M; Moric Peric, M; Pejsa, V; Perisa, V; Sedinic, M; Stoos-Veic, T; Zekanovic, I, 2022) |
| " He was diagnosed as primary myelofibrosis and treated with interferon-α, together with urate acid-lowing therapy (febuxostat 60 mg once daily)." | 3.88 | [A case of gout secondary to primary myelofibrosis]. ( Hao, YJ; Ji, LL; Zhang, ZL, 2018) |
| "Primary (PMF) and secondary myelofibrosis (SMF) are myeloproliferative neoplasms characterized by high cellular turnover and substantial risk of thrombosis and death." | 1.72 | Higher serum uric acid is associated with higher risks of thrombosis and death in patients with primary myelofibrosis. ( Galusic, D; Holik, H; Krecak, I; Kusec, R; Lucijanic, M; Moric Peric, M; Pejsa, V; Perisa, V; Sedinic, M; Stoos-Veic, T; Zekanovic, I, 2022) |
| "Patients with myelofibrosis had echocardiographic evidence of PH more often than patients with other MPNs (p < 0." | 1.56 | Association of Disease Subtype and Duration with Echocardiographic Evidence of Pulmonary Hypertension in Myeloproliferative Neoplasm. ( Akgun-Cagliyan, G; Kaya, E; Kilic, O; Ozen, F; Senol, H; Yaylali, YT; Yilmaz, S, 2020) |
| "No identifiable cause of secondary myelofibrosis." | 1.26 | [Acute or subacute myelofibrosis]. ( Bernard, J; Brière, J; Brière, JF; Castro-Malaspina, H, 1976) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 16 (84.21) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (5.26) | 24.3611 |
| 2020's | 2 (10.53) | 2.80 |
| Authors | Studies |
|---|---|
| Yaylali, YT | 1 |
| Yilmaz, S | 1 |
| Akgun-Cagliyan, G | 1 |
| Kilic, O | 1 |
| Kaya, E | 1 |
| Senol, H | 1 |
| Ozen, F | 1 |
| Lucijanic, M | 1 |
| Krecak, I | 1 |
| Galusic, D | 1 |
| Sedinic, M | 1 |
| Holik, H | 1 |
| Perisa, V | 1 |
| Moric Peric, M | 1 |
| Zekanovic, I | 1 |
| Stoos-Veic, T | 1 |
| Pejsa, V | 1 |
| Kusec, R | 1 |
| Ji, LL | 1 |
| Hao, YJ | 1 |
| Zhang, ZL | 1 |
| LASTER, L | 1 |
| MULLER, AF | 1 |
| Rojer, RA | 1 |
| Mulder, NH | 1 |
| Nieweg, HO | 1 |
| Brière, J | 1 |
| Castro-Malaspina, H | 1 |
| Brière, JF | 1 |
| Bernard, J | 1 |
| Klimova, NF | 1 |
| Pilipas, VA | 1 |
| Alvsaker, JO | 2 |
| Kühböck, J | 1 |
| Peskar, BM | 1 |
| Vormittag, W | 1 |
| Gilbert, HS | 1 |
| Hunstein, W | 1 |
| Hauswaldt, C | 1 |
| Presant, CA | 1 |
| Safdar, SH | 1 |
| Ward, HP | 1 |
| Block, MH | 1 |
| Richter, R | 1 |
| Hermanny, G | 1 |
| Hofer, E | 1 |
| Stobbe, H | 1 |
| Lewis, SM | 1 |
| Pettit, JE | 1 |
| Tattersall, MH | 1 |
| Pepys, MB | 1 |
| Yü, TF | 1 |
| Hooey, MA | 1 |
| Crookston, JH | 1 |
| Squires, AH | 1 |
| Garrod, PR | 1 |
| McSwiney, RR | 1 |
| Bold, AM | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Study of Pulmonary Hypertension in Patients With Chronic Myeloproliferative Disorders at Sohag University Hospital[NCT04843475] | 150 participants (Anticipated) | Observational | 2021-05-01 | Not yet recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 reviews available for uric acid and Agnogenic Myeloid Metaplasia
| Article | Year |
|---|---|
The spectrum of myeloproliferative disorders.
Topics: Blood Platelets; Cell Differentiation; Diagnosis, Differential; Hematocrit; Hematopoietic Stem Cells | 1973 |
[Myelofibrosis (author's transl)].
Topics: Antineoplastic Agents; Bone Marrow Examination; Folic Acid; Histamine; Humans; Hypertension, Portal; | 1974 |
The natural history of agnogenic myeloid metaplasia (AMM) and a critical evaluation of its relationship with the myeloproliferative syndrome.
Topics: Adrenal Cortex Hormones; Alkaline Phosphatase; Androgens; Anemia; Animals; Blood Cell Count; Blood C | 1971 |
16 other studies available for uric acid and Agnogenic Myeloid Metaplasia
| Article | Year |
|---|---|
Association of Disease Subtype and Duration with Echocardiographic Evidence of Pulmonary Hypertension in Myeloproliferative Neoplasm.
Topics: Adult; Aged; Bone Marrow Neoplasms; Echocardiography; Female; Humans; Hypertension, Pulmonary; Male; | 2020 |
Higher serum uric acid is associated with higher risks of thrombosis and death in patients with primary myelofibrosis.
Topics: Humans; Male; Primary Myelofibrosis; Prognosis; Retrospective Studies; Risk Factors; Thrombosis; Uri | 2022 |
[A case of gout secondary to primary myelofibrosis].
Topics: Arthritis, Gouty; Febuxostat; Gout; Gout Suppressants; Humans; Male; Middle Aged; Primary Myelofibro | 2018 |
Uric acid production in a case of myeloid metaplasia associated with gouty arthritis, studied with N15 labeled glycine.
Topics: Arthritis, Gouty; Glycine; Gout; Humans; Metaplasia; Primary Myelofibrosis; Research; Uric Acid | 1953 |
'Classic' and 'acute' myelofibrosis. A retrospective study.
Topics: Acute Disease; Blood Cell Count; Blood Sedimentation; Bone Marrow; Hemoglobins; Humans; L-Lactate De | 1978 |
[Acute or subacute myelofibrosis].
Topics: Acute Disease; Adult; Aged; Alkaline Phosphatase; Bone Marrow Examination; Cell Survival; Erythrocyt | 1976 |
[Characteristics of uric acid metabolism in myelofibrosis].
Topics: Adult; Aged; Humans; Kidney; Middle Aged; Primary Myelofibrosis; Uric Acid | 1976 |
Uric acid in human plasma. V. Isolation and identification of plasma proteins interacting with urate.
Topics: Adolescent; Adult; Aged; Alpha-Globulins; Blood Protein Electrophoresis; Chromatography, Gel; Chroma | 1966 |
[A "myeloproliferative syndrome" of long duration (author's transl)].
Topics: Aged; Arthritis; Bone Marrow; Chronic Disease; Diagnosis, Differential; Humans; Leukemia, Myeloid; M | 1974 |
Oxymetholone in myelofibrosis and chronic lymphocytic leukemia.
Topics: Aged; Anemia, Aplastic; Blood Cell Count; Blood Platelets; Blood Transfusion; Chemical and Drug Indu | 1973 |
[Secondary hyperuricemia in hemoblastosis].
Topics: Blood Cell Count; Humans; Leukemia; Myeloproliferative Disorders; Nephrosis; Polycythemia Vera; Prim | 1971 |
Myelosclerosis and paroxysmal nocturnal haemoglobinuria.
Topics: Adult; Alkaline Phosphatase; Bilirubin; Blood Proteins; Bone Marrow Examination; Chromium Isotopes; | 1971 |
Uric acid in human plasma. IV. Investigations on the interactions between urate and the macromolecular fraction in plasma from healthy individuals and patients with diseases associated with hyperuricemia.
Topics: Adolescent; Adult; Aged; Blood; Chemical Phenomena; Chemistry; Female; Gout; Hodgkin Disease; Humans | 1965 |
Secondary gout associated with myeloproliferative diseases.
Topics: Anemia, Hemolytic; Female; Gaucher Disease; Gout; Humans; Kidney Calculi; Leukemia, Myeloid; Male; N | 1965 |
Myeloproliferative disease complicated by megaloblastic anemia and hyperuricemia.
Topics: Anemia, Macrocytic; Blood; Blood Coagulation Disorders; Busulfan; Enzyme Therapy; Epistaxis; Female; | 1965 |
Investigation of renal excretion of phosphate and urate.
Topics: Adult; Gout; Humans; Middle Aged; Phosphates; Primary Myelofibrosis; Uric Acid; Urinary Calculi | 1966 |